CVS Surges on Regulatory Relief, Medicare Advantage Push: Time to Buy?

Key Takeaways CVS stock has jumped 53.7% in 2025 on strong operations and a friendlier regulatory landscape. Removal of PBM and Medicare Advantage cuts boosts CVS' Caremark and Aetna business lines. CVS' digital care push, cost savings and expanded access are reinforcing its 2025 growth trajectory.CVS Health (CVS) has seen its stock surge by 53.7% in 2025, fueled by a potent combination of strong operational performance and a favorable regulatory outlook. The company raised its full-year 2025 EPS guidance ...